Treatment of NF1-related plexiform neurofibroma with trametinib; a single arm, open-label trial with the goals of volumetric partial remission and pain relief
Latest Information Update: 16 Apr 2024
At a glance
- Drugs Trametinib (Primary)
- Indications Plexiform neurofibroma
- Focus Therapeutic Use
- Acronyms plexifpc
- 10 Apr 2024 Planned End Date changed from 1 Dec 2023 to 15 Dec 2024.
- 10 Apr 2024 Planned primary completion date changed from 1 Jul 2023 to 15 Jul 2024.
- 28 Mar 2023 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.